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Prognostic factors in non-Hodgkin's lymphoma: the
importance of symptomatic stage as an adjunct to the Kiel
histopathological classification
R.C.F. Leonard, J. Cuzick, I.C.M. MacLennan, R.I. Vanhegan, P.H. Mackie,
C.V. McCormick & the Oxford Lymphoma Group*
Summary A prospective study of prognostic factors for patients with non-Hodgkin's lymphoma was carried
out based on the Kiel histopathological classification. Other presentation features assessed for prognostic
value included clinical features, haematological and biochemical findings, and immunochemical findings. The
most powerful factors that emerged were the presence or absence of systemic symptoms and the
histopathological grade of malignancy of the lymphoma (whether low or high grade). These 2 factors were
largely independent. Clinical Stage I disease also carried a good prognosis, but beyond this, staging gave little
further prognostic information. Nine of the group of 15 patients with Stage I high grade lymphoma have
achieved prolonged disease-free survival after local therapy only. After allowing for histopathology and
symptom assessment in patients with Stage II-IV disease, other factors, with the exception of C-reactive
protein levels, were of minor importance.
Modern understanding of the heterogeneity and
differentiation pathways of lymphocytes has made
possible a more rational classification of
neoplastic disease of lymphoid cells. This approach
has been adopted particularly by the groups at Kiel
(Gerard-Marchant et al., 1974; Lennert, 1978)
and the University of Southern California (Lukes &
Collins, 1975). As yet there have been few data
published on the usefulness of these classifications
in prospective clinical studies. In this paper we
report the results of the use of the Kiel classification
of non-Hodgkin's lymphoma. We show that this
provides a useful means of distinguishing groups of
patients with differing prognoses. However, it is
clear from this study that symptomatic staging and,
to a lesser extent other factors, give important
additional prognostic information. We conclude
that histopathological groupings are only some of a
number of important factors which must be
considered in planning the management of patients
with this group of disease.
presentation have been studied in 199 patients with
non-Hodgkin's lymphoma (NHL) presenting to
clinicians of the Oxford Lymphoma Group between
January 1976 and April 1979. A further 10 patients
were diagnosed with NHL but received no follow-
up and have not been included. An additional 5
patients were lost during follow-up and were
censored at the time they were last known to be
alive. All other patients were followed until death
or 1 September 1981. By this date 102 deaths (51%)
had occurred. The median observation time was 39
months.
Eligibility
All new cases of non-Hodgkin's lymphoma
including patients with chronic lymphocytic
leukaemia (CLL), irrespective of age, were eligible
for the study. Patients who had previous cytotoxic
drug therapy or radiotherapy for lymphoma were
not eligible.
Patients and methods
Clinical and laboratory features observed at
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Histological classification
This was based on the classification laid down by
the Kiel convention of histopathologists. The
histopathological groups recognised are shown in
Table I together with the relative death rates for
each group. Subdivision of the mixed
centrocytic/centroblastic tumours into follicular,
follicular plus diffuse and diffuse was attempted.
However, extensive histological examination of all
tissue available, including extranodal tissues,
showed that the great majority of these patients fell
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Table I Distribution of NHL patients according to the Kiel classification
2-year Relative
Histopathological Number of survival death
groups patients (%) probabilities rate
Low grade ML
Centroblastic-
Centrocytic and
Centrocytic 64 (32) 72 0.76
Skin Lymphoma 6 (3) 84 0.25
ML
Lymphocytic including
chronic lymphocytic
leukaemia 48 (24) 79 0.61
ML
Lymphoplasmacytoid 15 (8) 57 1.32
High grade ML
Centroblastic 6 (3) 34 1.94
ML
Immunoblastic 19 (10 42 1.73
Histiocytic
tumours 9 (4) 34 1.80
ML
Unclassified 24 (12) 43 1.46
ML
Lymphoblastic 8 (4) 15 4.27
199 (100) 1.00
ML=Malignant Lymphoma
into the follicular plus diffuse category. Single
section inspection leads to a false impression of the
number of patients in the other 2 categories.
Centrocytic lymphoma was diagnosed in only those
5 patients in whose tumours were strictly no
centroblasts present. This group was considered too
small to analyse separately from the patients with
mixed centroblastic/centrocytic lymphoma.
Malignant lymphoma lymphocytic diffuse included
all patients with accumulations of small round cells
in the bone marrow. Twenty-six of the 48 patients
in this category had blood lymphocyte counts
<15 x IO I1-. No striking difference was observed
between survival in patients with blood lymphocyte
counts below and above this value and the patients
are included as a single group in this study.
The skin lymphoma group was a heterogeneous
collection of patients, 5 with low grade lymphoma
principally involving the skin and one with high
grade lymphoma.
Large cell lymphomas which could not be
readily classified as immunoblastic, centroblastic,
lymphoblastic or of histiocytic origin were placed in
an unclassified high grade lymphoma group. It is
recognised that histiocytic tumours are not strictly
lymphoid malignancies but they are included as a
small group within this study.
Clinical staging
Conventional staging for spread identifying stages
I-IV and IE-IIIE was used. Patients with
malignant lymphoma lymphocytic have stage IV
disease by definition and have been excluded from
this staging analysis. Staging involved chest x-ray,
skeletal survey examination of marrow particle
sections from 3 sites. In patients with apparent
stage I or II disease after these procedures
lymphangiogram and liver biopsy were performed.
Lymphangiogram was performed in other patients
to help assess tumour load. Laparotomy was only
performed in patients where disease was not
demonstrable outside the abdomen. Patients with
IE disease were defined as those with single site
tumour not involving local nodes.PROGNOSTIC FACTORS IN NON-HODGKINS LYMPHOMA 93
Symptomatic staging was based upon the Ann
Arbor criteria (Carbone et al., 1971). Details are
given in the results.
Treatment
Patients were allocated by their physicians to one of
5 specified treatment policies. Histopathological
appearance, stage, age and performance status were
the main factors used in determining which
treatment policy was chosen. The treatment policies
were:
(a) No therapy after initial diagnostic surgery. This
conservative policy was only adopted for
asymptomatic patients with low grade
lymphoma and low tumour load whose disease
was not obviously progressing. However, 6
patients with high grade stage IE lymphoma of
the gut without local nodal involvement were
also managed without cytotoxic therapy after
full surgical removal of their tumour.
(b) Local radiotherapy for patients with low grade
asymptomatic lymphoma which was not
obviously progressive and where single nodes
were a problem. Minimum fields were used and
dosage was based upon tumour response.
(c) Local radiotherapy for patients with stage I
high grade lymphoma outside the gut.
Maximum practicable doses were given and
adjacent nodes were irradiated. Depending on
the site this varied between 37.5Gy and 45.0Gy
given in 1.25Gy fractions in 8 patients. One
patient received 40Gy in 12 fractions.
(d) Gentle chemotherapy with intermittent
cyclophosphamide, vincristine and prednisone
(Figure 1). This was used for all patients with
low grade lymphoma other than those indicated
in (a) and (b).
1I1ll 1-111 I'' 11111
(e) Aggressive chemotherapy given to patients with
disseminated high grade lymphoma (Figure 2a,
b). Some patients were also given local
radiotherapy.
Immunoglobulin and acute phase protein
quantitation was carried out using radial
immunodiffusion against constant standards
(Mancini et al., 1965).
Bone marrow involvement was assessed using
histological sections of bone marrow particles. In
most cases particles were examined from the
sternum and both iliac crests. Identification of
tumour islands was facilitated by the use of
immunoperoxidase staining for lysozyme to identify
normal myeloid tissue.
Statistical methods employ Kaplan-Meier
survival curves and differences between survival
curves are assessed by log rank statistics (Peto et
al., 1976, 1977).
Results
Two factors, the histopathological group and the
presence of systemic (B) symptoms, were found to
be the most powerful determinants of prognosis and
these exhibited considerable independence. After
they were taken into consideration, other factors
provided little additional information. Two notable
exceptions were the improved survival of the
patients with localised (Stage I or IE) disease and
the poorer prognosis associated with elevated levels
of C-reactive protein within the group of
asymptomatic patients.
Histopathology
The distribution of patients according to the Kiel
classification is shown in Table I along with the
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Figure 2 Intensive chemotherapy regime for NHL induction and consolidation (a); and maintenance (b).
U/d =units per day. VCR =Vincristine. 6TG=6 Thioguanine. MTX=methotrexate. 6MP =Mecaptopurine.
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Figure 3 Survival by histopathological group of patients with NHL. DLL=malignant lymphoma
lymphocytic diffuse including CLL. CC and CB/CC=malignant lymphoma centrocytic with
centroblastic/centrocytic. LPC=malignant lymphoma lymphoplasmacytoid. UNCL=unclassified high grade
malignant lymphoma. IB=malignant lymphoma immunoblastic. LVB=malignant lymphoma lymphoblastic.
HIS=histiocytic tumour. In the case of the histiocytic and lymphoblastic group the longest surviving patient
had not been in the trial for 4 years at the time of analysis. The vertical lines on the survival curves represent
censor times.
estimated 2-year (actuarial) survival probabilities. A
life table comparison is shown in Figure 3. The
well-established difference in survival between
patients with low grade (LGL) and high grade
(HGL) lymphomas is very clear (Figure 4). Within
the group of patients with low grade tumours those
with lymphoplasmacytoid lymphoma exhibit poorer
survival prospects (relative death rate 1.85, P=0.05).
Patients with other low grade lymphomas show a
remarkably similar life expectancy. Among patients
with high grade tumours, those with lymphoblastic
lymphomas have the poorest outlook. The median
0
o
low grade lymphoma (133)
cm 75
E
CD 50 high grade lymphoma (66)
'2 25
Co .0
0-
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Figure 4 Survival by histopathological grade.
Numbers in brackets represent the total patients in
each group.
survival time is only 4 months and these patients
fare significantly worse than those with other high
grade lymphomas (relative death rate 2.19, P=0.03).
However, as the largest difference in survival relates
to the simpler division of patients into those with
high grade vs. low grade lymphoma (Figure 4), we
will only consider this distinction when examining
other factors.
Symptoms
The presence or absence of the following symptoms
were noted in all patients:
(i) Weight loss> 10% over 6 months or less
(ii) Fever> 39°C or night sweats.
Figures 5, 6 indicate how these symptoms related to
survival. If patients with either (i) or (ii) or both are
said to have B symptoms and all other are said to
be asymptomatic, asymptomatic patients fare better
than patients with B symptoms.
The importance ofthe division according to symp-
toms remains after correction for histopathological
group. Figure 6 shows that among patients with
low grade lymphomas, those in the asymptomatic
group fared significantly better than those with
symptoms (x2= 10.10, P=0.002). This difference
occurs also among high grade lymphoma patients
(x2-7.44, P=0.006) (Figure 6). The overall x2 for
symptoms after correcting for pathology was 16.9
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Figure 5 The effect of symptoms on survival. The
profile labelled "systemic symptoms present"
represents patients with B symptoms as classified in
the text. The "symptoms absent" patients are all those
without B symptoms. The numbers in brackets
represent the total patients in each group.
which is 54.9% of the uncorrected value. Also, the
importance of pathology was not secondary to
symptoms as the x2 for pathological grade was 9.0
after correcting for symptoms which was 39.6% of
the uncorrected value. Thus symptoms and
pathology are 2 relatively independent predictors of
survival and with them we can establish 4 sub-
groups of patients whose survival is shown in
Figure 6. Asymptomatic low grade lymphoma
patients survive longest, symptomatic low grade
lymphoma and asymptomatic high grade
lymphoma fare about equally and symptomatic
high grade lymphoma patients do least well. In the
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75
E50 tL
Cu~ ~ L
0)
50
,0
20
a.
sequel we will consider which factors can provide
further prognostic information after this initial
subdivision.
Stage
The relevance of stage of the disease has been
studied in the 151 patients whose diagnosis was not
malignant lymphoma lymphocytic (including
chronic lymphocytic leukaemia). Patients with
localised disease (Stage I and IE) fared better than
remaining patients. As seen from Table II, patients
with Stages II, III and IV had similar survival and
the important factor here seems to be simply
verification that the disease is restricted to one site.
Localised disease was found in 23% of these 151
patients and, except for 2 cases, was associated with
a lack of B symptoms. It will be seen from Table II
that in high grade lymphoma the effect of
symptoms is largely predictable by analysis of stage.
Twenty of 65 (31%) asymptomatic patients with low
grade lymphomas and 13 of 30 (43%) asymptomatic
patients with high grade lymphomas presented with
localised diseases and in each group this condition
was associated with improved survival. Of the 15
patients with stage I high grade lymphoma, 9 are
still in complete remission. They have follow-up
times of 26, 29, 31, 36, 37, 43, 51, 55 and 60 months.
Six of these patients had gastro-intestinal tumours
and they were treated by surgical excision only. The
remaining 9 patients received eradicative
radiotherapy. Long-term remissions in relation to
site in this group was seen in 4/6 gastro-intestinal,
3/5 nasopharyngeal, 0/1 testicular, 1/2 bone and 0/1
skin tumours.
Time from entry (y)
Figure 6 The effect of B symptoms in different histopathological grades. LGL=low grade lymphoma.
HGL= high grade lymphoma. Other numbers are the same as in Figure 3.PROGNOSTIC FACTORS IN NON-HODGKINS LYMPHOMA 97
Table II Observed and expected deaths by clinical stage broken down by grade and symptoms for all patients except
diffuse lymphocytic lymphoma and chronic lymphocytic leukaemia.
Combinedgroups
Combined stratified by
groups grade and
Clinical stage Low grade A Low grade B High grade A High grade B (Uncorrected) symptoms
N O E O/E NOE O/E NOE O/E N O E O/E N O E O/E N O E O/E
I and Ie 20 2 9.01 0.22 0 0 0 - 13 4 9.17 0.44 2 2 2.88 0.69 35 8 25.59 0.31 35 8 21.06 0.38
II and Ile 13 5 4.82 1.04 2 0 2.05 0.0 7 5 3.08 1.62 6 6 4.36 1.37 28 16 14.27 0.12 28 16 14.31 1.12
III and IlIe 13 7 4.82 1.45 7 4 4.21 0.95 5 4 2.86 1.40 8 7 6.46 1.08 33 22 17.84 1.23 33 22 18.36 1.20
IV 19 11 6.36 1.73 11 9 6.74 1.34 5 4 1.89 2.12 20 1415.29 0.92 55 38 26.30 1.45 55 38 30.27 1.26
x2 I and Ie
vs all others 9.62, P=0.002 5.90, P=0.02 0.05, P=0.83 16.6, P<0.0001 11.4, P=0.0007
Clinical stage based upon clinical and radiological and bone marrow data.
A=asymptomatic, B=systemic symptoms.
N=number ofpatients, 0=observed deaths, E=expected death.
Effect of symptoms and stage statistically tested by log rank analysis of actuarial survival curves.
Site ofdisease
Survival by site of disease is presented in Table III.
It is apparent from these data, that patients with
extranodal disease only, have a better-than-average
prognosis. This is particularly apparent among
patients in which disease is found only in the blood
or bone marrow. However, most of this latter group
(10/13) were patients with malignant lymphoma
lymphocytic. It is apparent from Table III that
patients with disease in a single group of superficial
nodes have a better prognosis and patients with
general disease of the lymphoid system have a
poorer outlook, but the magnitude of these
differences is reduced considerably after correction
for histological grade and symptoms is made.
Acute phase proteins
Acute phase proteins were measured on 118
patients (59%). Elevated levels of C-reactive protein,
a, anti-trypsin, or oroso mucoid each indicated a
relatively poor prognosis. However, in the last 2
instances this relationship was secondary to the
observation of symptoms. However, the predictive
value of C-reactive protein was not lost after
correction for symptoms and histopathology (Table
IV). Figure 7 shows that an elevated level of C-
reactive protein was found in 37% of asymptomatic
patients and within that group was a strong
predictor of short survival. In contrast, a high
percentage of symptomatic patients had an elevated
level, but within this group the observation was of
little prognostic significance.
Age and sex
Male patients (54%) had significantly poorer
prognosis (P=0.02) (Table IV). Patients over 60
years fared less well than younger patients and
survival prospects were still further reduced in
patients over 70 (P=0.003, trend). (Table IV) After
correction for histopathological group and
symptoms, a stronger gradient with age was
apparent which was highly significant (P=0.0001,
trend). Thus, within each sub-group age was an
important factor and the corrected estimates of the
effect were larger because older patients tended to
present with better histology (usually M.L.
lymphocytic).
Other haematologicalfactors
Depressed haemoglobin levels were associated with
poorer survival (Table IV). The importance of this
factor was most apparent in the asymptomatic low
grade lymphoma group where the 20 patients (19%)
with levels below 11 g/dl had a death rate more
than twice as high as the total group (2= 13.8, P
=0.0002). Depressed haemoglobin levels led to only
a slightly worse prognosis in the other sub-groups
but the corrected overall difference in all patients
was still highly significant (x2 = 11.7, P=0.0006). No
further increase in mortality rates could be seen in
patients with a greater degree of anaemia
(<8gdl-' or <lOgdl-').
Platelet counts < 150 x 109 1 were also a sign of
poorer survival prospects (Table IV). The predictive
power of this variable was less than for
haemoglobin levels (P=0.001), but the effects did98 R.C.F. LEONARD et al.
Table III Observed and expected deaths
involvement.
according to site of
Correctedfor
Site Uncorrected grade and symptoms
NO E O/E N O E O/E
Blood and bone marrow
only 13 3 8.38 0.36 13 3 5.51 0.54
Other extranodal site
only 28 9 16.28 0.55 28 9 16.40 0.55
Single superficial
group of nodes only 27 8 16.24 0.49 27 8 12.20 0.66
Single superficial
group of nodes and
extranodal involvement 41 23 19.67 1.17 41 23 19.72 1.17
Mediastinal or
abdominal nodes only 39 24 19.13 1.25 39 24 19.98 1.20
Spleen predominantly 24 15 11.79 1.27 24 15 11.56 1.30
General nodal
involvement 27 20 10.52 1.90 27 20 16.62 1.20
X2 (Heterogeneity) x2 22.56 (6df)
P=0.001 x2 11.83 (6df) P=0.07
N=number of patients, 0=observed deaths, E=expected deaths.
Effect of symptoms and stage statistically tested by log rank analysis of
actuarial survival curves. df=degrees offreedom.
°100
(M 75 c
._
E 4I 50
0
= 25
.0
0
L-
a.
C-RPG 10 mg/I (51)
CR RP>10 mg/l (30)
asymptomatic patients
Time from entry (y)
3 4
Figure 7 The effect of elevated serum C-reactive
protein levels in patients without B symptoms.
:
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Table IV Secondary prognostic factors in NHL
Relative death-
rate after correc-
Relative death- tionfor symptoms
rate and pathological Number
Factor Level uncorrected group (per cent)
C-reactive
protein
x2
al-antitrypsin
x2
Oroso-mucoid
x2
Age
x2 (trend)
Sex
x2
Haemoglobin
x2
Platelets
x2 (trend)
Neutrophils
x2 (heterogeneity)
Lymphocytes
x2 (trend)
<10mg/l
>10
.400yog/
>400
< 140 g/l
>140
.45
46-60
61-70
70+
Male
Female
.1 Ig/l
>1 g/l
100x 109/
100-150
> 150
42x 109/l
2-6
>6
<.1 x 109/1
1-1.5
>1.5
0.58
1.63
15.83 P=0.0001
0.83
2.68
17.56, P=0.0001
0.52
1.34
9.70, P= 0.002
0.73
0.68
1.15
1.78
8.77, P=0.003
1.22
0.77
5.33, P=0.02
1.90
0.83
15.86, P=0.0001
1.97
1.31
0.85
10.19, P=0.001
1.47
0.70
1.60
15.50, P=0.0004
1.44
1.23
0.73
7.32, P=0.007
0.66
1.38
9.23, P=0.002
0.90
1.51
3.69, P=0.05
0.61
1.21
5.99, P=0.01
0.64
0.67
1.16
2.48
16.20, P= 0.0001
1.20
0.78
4.54, P=0.03
1.71
0.84
11.70, P=0.0006
1.63
1.53
0.86
7.57, P=0.006
1.65
0.75
1.28
10.17, P=0.006
1.23
1.26
0.78
3.54, P=0.06
Relative death-rates are indicated to show the magnitude of the predictive value of each minor
prognostic factor. The overall death-rate is unity and sub-groups with values larger than one
correspond to a poorer-than-average survival.
remain after correction for the major prognostic
groups (P=0.006). An effect was seen in each of the
4 major sub-groups of patients.
The presence of neutropenia (<2 x I0'1-) or
neutrophilia (>6x i091-') were both minor
negative prognostic factors of about equal
magnitude and in each case the strength of this
variable was little changed upon correction for
symptoms and pathological group (Table IV).
While depressed lymphocyte counts were
associated with a slightly worse prognosis, this
effect was largely accounted for by differences in
symptoms and/or pathology and was not quite
significant (X2 =3.54, P =0.06) after correction for
these factors (Table IV). Nevertheless, the finding of
lymphopenia frequently proved to be a strong
diagnostic indicator leading to the subsequent
confirmation of lymphoma. Neither the ESR nor
polyclonal immunoglobulin levels were associated
with prognosis.
61 (52)
57 (48)
101 (86)
17 (14)
43 (36)
75 (64)
36
46
90
26
(18)
(24)
(45)
(13)
108 (54)
91 (46)
41 (21)
154 (79)
20 (11)
19 (10)
142 (79)
21 (12)
105 (59)
51 (29)
36 (27)
30 (22)
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Discussion
This analysis indicates that the presence or absence
of B symptoms and histopathological grade of
malignancy are the most helpful independent factors
in predicting prognosis. Many reports of survival in
non-Hodgkin's lymphoma have not indicated the
influence of symptomatic grade. Among those that
have, the results reported are variable. Bloomfield et
al. (1974); Rudders et al. (1979) and Glick et al.
(1982) noted B symptomatic grade as carrying an
unfavourable prognosis. Fisher et al. (1979) in a
study of 66 patients with diffuse histiocytic (high
grade) lymphoma, however, saw no adverse effect
associated with B symptoms. Jones et al. (1973) in a
substantial study of 405 cases reported a strong
correlation between stage and the presence of B
symptoms. They show survival curves for various
Rappaport histopathological groups with stage 4
disease with and without B symptoms. No more
than marginal trends to adverse prognosis are
associated with the presence of B symptoms. As in
the study of Jones et al., the incidence of B
symptoms in our patients increases with stage
(Table II). The effect of B symptoms in high grade
lymphoma is almost entirely attributable to the
good performance of stage 1 and lE patients
without B symptoms. Our results, therefore, for
high grade disseminated disease are the same as
those reported by Jones et al. (1973). The differences
shown in Figure 6 between symptomatic high grade
and asymptomatic high grade can be largely
predicted by stage. The prognostic significance of
symptoms, however, in low grade lymphoma is not
solely associated with stage.
The Kiel system of classification indicates 2
subgroups, one within the low grade lymphomas,
one within the high grade lymphomas, each of
which has a somewhat different prognosis from the
other histopathology groups within each grade.
Thus the patients with lymphoplasmacytoid
lymphoma have a significantly poorer outlook than
other patients with low grade lymphoma. This
reflects the results reported by Meusers et al. (1980)
in a substantially larger group of patients. However,
there is marked heterogeneity within the
lymphoplasma cytoid group. All 6 patients in our
study dying in the first year who had this type of
tumour were deemed sufficiently ill to require
immediate systemic chemotherapy. However, a
number of the remaining 9 patients have remained
well throughout the study with no treatment after
initial diagnosis. This exemplifies the marked
differences in disease activity within certain
histopathological groups, which may be clinically
rather than microscopically identifiable. The other
subgroup deserving special mention comprises those
patients who had lymphoblastic lymphoma. These
had a very poor outlook compared with any
other histopathological group. Although not
reported in this paper, analysis by treatment of
these patients indicated that they were given full
doses of the intensive chemotherapy. Also 7 of the 8
patients who died did so because of advanced
disease rather than from inter-current infections or
other preventable problems. The poorer survival of
these subgroups is in accordance with the findings
of Meusers et al. (1979). A small group of patients
with exclusively centroblastic lymphoma was
included in the high grade group. This was not
sufficiently large to allow meaningful comparison
with the other high grade groups. Meusers et al.
(1980) found a markedly better survival in patients
with centroblastic, compared with those with
immunoblastic lymphoma. However, this reflects a
poor survival in their patients with immunoblastic
lymphoma compared to the group described in this
paper. These differences in survival of patients with
immunoblastic lymphoma may reflect differences in
chemotherapy used by the two study groups. High
grade lymphoma presenting with stage I disease
carries a relatively favourable prognosis. These
patients were treated either with surgical excision or
biopsy excision combined with irradicative local
radiotherapy. Nine of these patients are still alive
and apparently disease-free. This would support the
view that at least a proportion of high grade
lymphomas originate in a static end cell which does
not recirculate. The results in stage IE gastro-
intestinal high grade disease correlate well with
those of the large retrospective study of Weingrad
et al., (1982). Bitran et al., (1977); Chen et al., (1979)
and Levitt et al., (1980) have also emphasised the
curability of localised high grade lymphoma after
local treatment.
There is a relative lack of non-histopathological
data in the evaluation of non-Hodgkin's lymphoma,
but there are some points of interest when our data
are compared with the results of other workers,
(Bloomfield et al., 1967a,b; 1977; Cabanillas et al.,
1978; Dumont et al., 1975; Brown et al., 1975;
Portlock & Rosenberg 1977).
In the study of haematological findings at
diagnosis in 140 cases by Bloomfield et al. (1977),
the abnormalities in the blood did not correlate
with survival in the absence of bone marrow
involvement. Against this, the present study
indicates that both high or low as opposed to
normal neutrophil counts, low lymphocyte count,
low platelet count and low haemoglobin are all
associated with poor prognosis. With the exception
of lymphocyte counts, and high neutrophil values,
these associations remained apparent after
adjustment for histopathology and symptoms andPROGNOSTIC FACTORS IN NON-HODGKINS LYMPHOMA 101
they would appear to provide useful secondary
prognostic information. Our rate of detection of
disease in the marrow in low grade lymphoma is
somewhat lower than that of othet workers. This
may have been due to the particle sectioning
technique missing paratrabecular involvement,
especially in follicle centre cell lymphomas. We have
noticed this pattern in more recent studies where
trephine biopsy technique has been used. However,
the combination of multiple site aspiration and
histological processing of particles in high grade
lymphomas has produced a rate of detection
comparable with results of other workers; (Dick et
al., 1974; Rosenberg et al., 1975). Thus it is felt
that our failure to find a correlation between bone
marrow involvement and prognosis in patients with
Stage II-IV high grade lymphoma, is unlikely to be
due to failure to detect disease.
It may be postulated that the presence of
systemic symptoms and disturbances of the acute
phase proteins is related to prognosis by way of
bulk of disease. Although disease bulk is very
difficult to assess, an attempt was made to divide
patients into those who had bulky and non-bulky
disease and this showed a slight correlation with a
presence of symptoms. However, when symptomatic
stage was considered, the presence or absence of
bulk disease was of only marginal value. It must be
concluded that it is easier to assess symptoms rather
than extent of bulk disease and that the exercise is
more valuable. The effect upon prognosis of the
elevation of C-reactive protein in asymptomatic
patients is important and suggests that it might be
wise to group these patients with those who have
systemic symptoms.
This analysis indicates that it is reasonable to
divide patients according to grade of malignancy
and the presence or absence of symptoms in the
first instance and that treatment should be based
upon this subdivision providing that the stage of
disease is beyond stage I. Within the four strata
produced by this analysis it seems reasonable to
treat the low grade asymptomatic patients purely
for local problems following the principles of
Portlock & Rosenberg (1977). Patients with low
grade lymphoma and B symptoms will require
active intervention. However, long-term results in
this group with both combination and single agent
chemotherapy have been disappointing (Portlock et
al., 1976; McKelvy & Moon, 1977; Lister et al.,
1978). Patients with disseminated high grade
lymphoma all require aggressive treatment as their
disease is potentially curable (DeVita et al., 1975;
Berd et al., 1975; McKelvy & Moon, 1977). For
patients with lymphoblastic lymphoma a completely
different approach to chemotherapy is apparently
required.
We are grateful to the Leukaemia Research Fund for their
support of this study. A number of histopathologists
kindly gave helpful advice on cases with difficult histology.
We are particularly grateful to Dr E.L. Jones of the
Department of Pathology, University of Birmingham in
this respect.
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